Opendata, web and dolomites

THERAPROBES SIGNED

Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERAPROBES project word cloud

Explore the words cloud of the THERAPROBES project. It provides you a very rough idea of what is the project "THERAPROBES" about.

fsns    variability    directing    clinical    poor    intervention    near    recur    active    gastrointestinal    vascular    progression    fsn    specificity    scales    size    accuracy    solely    sites    ubiquitously    amenable    negatively    errors    inter    survival    therapeutic    regular    curative    diagnosing    requiring    silica    tumor    accurate    strategy    routine    patients    decrease    delineation    optical    permeability    detect    inherent    resection    physician    operator    compromises    tract    visualization    clinically    aggressive    marker    time    sensitive    biopsy    miss    minus    light    paradigm    subtle    white    disease    life    random    fluorescent    impacting    reliably    diagnostic    endoscopy    gitract    50    detection    asymptomatic    appearance    risk    applicable    surveillance    endoscopic    quality    contrast    nanoprobes    site    chance    symptomatic    lesions    rate    detected    successful    gi    agents    sampling    33    unmet    outcomes    tremendous    progress    augmented    true    critical    sensitivity    imaging    biodegradable    lesion    rates    misses    diagnosis    improves    treatments    ablation    accumulate    systemic    lack    80    accurately    25    patient    treatment    malignant   

Project "THERAPROBES" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions is critical for patient survival. Early detection of asymptomatic disease of the GItract improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Regular endoscopic surveillance in high-risk patients misses 25% of (pre)malignant lesions – the most clinically relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when malignant disease is detected, lack of sensitive contrast agents compromises delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. About 33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect those lesions with high sensitivity and specificity. To develop a clinically viable strategy, I propose to use biodegradable, fluorescent silica nanoprobes (FSN) that provide real-time visualization of the lesions over a range of scales during routine endoscopy. Since FSNs accumulate at the tumor sites solely due to their size and increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are amenable to curative therapeutic intervention.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPROBES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPROBES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PI3K MODULATORS (2019)

Identification and characterisation of new class of PI3K modulators in oncology

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More